Peter van Rossum, Radiation Oncologist at Amsterdam UMC, shared a post on LinkedIn:
“Back from three inspiring days at the Immunorad congress in Paris!
Together with my colleague Famke Schneiders, who has been active in this field for many years, we brought 3 of our talented Amsterdam UMC PhD students and a bright medical student, all presenting their work:
- Nora Purcell: RT + dual IO reactivates the immune system in stage IV NSCLC PD-L1 <50% progressing after chemo-IO.
- Pim Damen: Prediction model for radiation-induced lymphopenia also predicts durvalumab efficacy in stage III NSCLC.
- Mathijs Tomassen: Real-world PACIFIC data confirm durvalumab is safe and well-tolerated.
- Claudia Pronk: Meta-analysis shows adjuvant IO may be more effective than concurrent strategies.
We were also inspired by our colleague Idris Bahce and his talk on immunoPET in NSCLC.
Proud of our team, and grateful to the organizers, particularly Eric Deutsch, for bringing so much expertise together in such a magnificent setting!”
More posts featuring Immunorad on OncoDaily.